Détails de produit
Lieu d'origine: CHINE
Nom de marque: HBY
Certification: COA、HLPC、MR
Numéro de modèle: Rétatrutide 60 mg/flacon
Documents: Brochure du produit PDF
Conditions de paiement et d'expédition
Quantité de commande min: 5boxes
Prix: Négociable
Détails d'emballage: 60 mg/flacons, 10 flacons/boîte
Délai de livraison: 3-5 jours, à la réception du paiement
Conditions de paiement: T / T, Western Union, Moneygram
Capacité d'approvisionnement: 30000flacons/mois
Nom: |
Reta 60 mg à vendre |
Ch: |
2381089-83-2 |
MW: |
4845.444 |
MF: |
C223H343F3N46O70 |
Couleur: |
Blanc |
Matériel: |
Poudre |
Spécification: |
60 mg/ flacon, 10 flacons/ boîte |
MOQ:: |
5 boîtes |
Nom: |
Reta 60 mg à vendre |
Ch: |
2381089-83-2 |
MW: |
4845.444 |
MF: |
C223H343F3N46O70 |
Couleur: |
Blanc |
Matériel: |
Poudre |
Spécification: |
60 mg/ flacon, 10 flacons/ boîte |
MOQ:: |
5 boîtes |
Retarutide Review
Retatrutide (LY-3437943) powder is a weight loss drug developed by Eli Lilly and Company that is currently in Phase III clinical trials for obesity. It is used to treat type 2 diabetes, obstructive sleep apnea, osteoarthritis, obesity, and non-alcoholic fatty liver disease.Retatrutide peptide is a triple hormone receptor agonist for GLP-1, GIP, and GCGR receptors. By activating these receptors, Retatrutide may help regulate appetite, increase energy expenditure and improve glucose metabolism. This unique mechanism of action of Retatrutide makes Retatrutide raw powder and Retatrutide peptide finished bottles more promising in the weight loss market.Aea.ltd is a professional Retatrutide powder manufacturer in China, which provides high quality Retatrutide raw powder and Retatrutide customized peptide finished bottles at a reasonable price.
Chemical Property:
| Product Name: | Retatrutide |
| CAS No.: | 2381089-83-2 |
| Molecular Formula: | C223H343F3N46O70 |
| Molecular Weight: | 4845.444 |
| Sequence: |
Tyr- {Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile- {α-Me-Leu}-Leu-Asp-Lys- {diacid -C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln- {Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly -Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| Other names/Synonyms: | LY-3437943 |
| Storage Temp: | Please seal and store at 8°C–20°C |
What is the mechanism of action of Ridarutide?
As a triple agonist peptide diet pill to help control obesity, Ridarutide powder targets three different hormones in the body: gastric inhibitory peptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.
GIP and GLP-1
Blood Sugar Control
After Ritalin injection, eating food will raise blood sugar, producing GIP and GLP-1, which stimulate insulin secretion and increase insulin levels in the blood, lowering blood sugar and ultimately promoting weight loss.
Reduces Appetite
GLP-1 and GIP also affect appetite. They delay gastric emptying (GE), reducing hunger and increasing satiety, thus reducing food intake and achieving weight loss.
Glucagon
During prolonged periods of no carbohydrate intake (e.g., during sleep, adherence to a low-calorie diet, or intermittent fasting), glucagon promotes the breakdown of glycogen into glucose for energy, which in turn breaks down fat over a period of time, leading to weight loss.
Retaturtide powder works in a similar way to other weight loss medications such as Saxenda, Mounjaro and Wegovy. However, it is influenced by three hormones. This unique mechanism of action provides a multifaceted approach to controlling obesity and type 2 diabetes. By controlling blood glucose levels, delaying gastric emptying and regulating appetite, ritalopeptide powder is expected to be a powerful tool in the fight against obesity and related metabolic disorders.
Retatrutide VS Tirzepatide VS Semaglutide
| Items |
Semaglutide (Wegovy/Ozempic)
|
Tirzepatide (Mounjaro)
|
Retatrutide |
| Mechanism | GLP-1 receptor agonist | GLP-1 and GIP Receptor agonist | GLP-1, GIP, Glucagon receptor agonist |
| Dosage range | 0.25mg-2.4mg | 2.5mg-15mg | 1mg-12mg |
| Weight loss in clinic trial |
Wegovy: 14.9% of body weight after 68 weeks Ozempic: 6.1% of body weight after 52 weeks |
22.5% of body weight after 72 weeks | 22.5% of body weight after 72 weeks |
| Prices/cost | Semaglutide powder＜Tirzepatide powder＜Retatrutide powder | ||
| Effectiveness | Semaglutide powder＜Tirzepatide powder＜Retatrutide powder | ||
Retatrutide In Type 2 Diabetes
| Group | Dosage (mg) | Change in HbA1c at 24 weeks (%) | Change in HbA1c at 36 weeks (%) | Weight change (kg) |
| Placebo | 0 | -0.01 (0.21) | -0.13 (0.25) | -0.54 (0.73) |
| Retatrutide | 0.5 | -0.43 (0.20) | -0.64 (0.26) | -1.45 (0.80) |
| Retatrutide | 1.5 | -1.39 (0.14) | -1.64 (0.19) | -2.78 (0.64) |
| Retatrutide | 4 (increasing) | -1.30 (0.22) | -1.51 (0.25) | -2.51 (0.71) |
| Retatrutide | 8 (slowly increasing) | -1.99 (0.15) | -2.28 (0.18) | -3.42 (0.58) |
| Retatrutide | 8 (rapidly increasing) | -1.88 (0.21) | -2.13 (0.24) | -3.17 (0.67) |
| Retatrutide | 12 | -2.02 (0.11) | -2.36 (0.15) | -3.83 (0.51 |
